Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C

[Image: see text] The tumor suppressor protein p53 is inactivated in the majority of human cancers and remains a prime target for developing new drugs to reactivate its tumor suppressing activity for anticancer therapies. The oncogenic p53 mutant Y220C accounts for approximately 125,000 new cancer c...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephenson Clarke, Joseph R., Douglas, Leon R., Duriez, Patrick J., Balourdas, Dimitrios-Ilias, Joerger, Andreas C., Khadiullina, Raniya, Bulatov, Emil, Baud, Matthias G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667543/
https://www.ncbi.nlm.nih.gov/pubmed/36407959
http://dx.doi.org/10.1021/acsptsci.2c00164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667543/
https://www.ncbi.nlm.nih.gov/pubmed/36407959
http://dx.doi.org/10.1021/acsptsci.2c00164

Ejemplares similares